Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study

doi:10.1016/S1474-4422(12)70200-4

The Lancet Neurology

Volume 11, Issue 10, October 2012, Pages 868-877

https://doi.org/10.1016/S1474-4422(12)70200-4 Get rights and content

Summary

Background

Three subtypes of Alzheimer's disease (AD) have been pathologically defined on the basis of the distribution of neurofibrillary tangles: typical AD, hippocampal-sparing AD, and limbic-predominant AD. Compared with typical AD, hippocampal-sparing AD has more neurofibrillary tangles in the cortex and fewer in the hippocampus, whereas the opposite pattern is seen in limbic-predominant AD. We aimed to determine whether MRI patterns of atrophy differ between these subtypes and whether structural neuroimaging could be a useful predictor of pathological subtype at autopsy.

Methods

We identified patients who had been followed up in the Mayo Clinic Alzheimer's Disease Research Center (Rochester, MN, USA) or in the Alzheimer's Disease Patient Registry (Rochester, MN, USA) between 1992 and 2005. To be eligible for inclusion, participants had to have had dementia, AD pathology at autopsy (Braak stage ≥IV and intermediate to high probability of AD), and an ante-mortem MRI. Cases were assigned to one of three pathological subtypes—hippocampal-sparing, limbic-predominant, and typical AD—on the basis of neurofibrillary tangle counts in hippocampus and cortex and ratio of hippocampal to cortical burden, without reference to neuronal loss. Voxel-based morphometry and atlas-based parcellation were used to compare patterns of grey matter loss between groups and with age-matched control individuals. Neuroimaging was obtained at the time of first presentation. To summarise pair-wise group differences, we report the area under the receiver operator characteristic curve (AUROC).

Findings

Of 177 eligible patients, 125 (71%) were classified as having typical AD, 33 (19%) as having limbic-predominant AD, and 19 (11%) as having hippocampal-sparing AD. Most patients with typical (98 [78%]) and limbic-predominant AD (31 [94%]) initially presented with an amnestic syndrome, but fewer patients with hippocampal-sparing AD (eight [42%]) did. The most severe medial temporal atrophy was recorded in patients with limbic-predominant AD, followed by those with typical disease, and then those with hippocampal-sparing AD. Conversely, the most severe cortical atrophy was noted in patients with hippocampal-sparing AD, followed by those with typical disease, and then limbic-predominant AD. The ratio of hippocampal to cortical volumes allowed the best discrimination between subtypes (p<0·0001; three-way AUROC 0·52 [95% CI 0·47–0·52]; ratio of AUROC to chance classification 3·1 [2·8–3·1]). Patients with typical AD and non-amnesic initial presentation had a significantly higher ratio of hippocampal to cortical volumes (median 0·045 [IQR 0·035–0·056]) than did those with an amnesic presentation (0·041 [0·031–0·057]; p=0·001).

Interpretation

Patterns of atrophy on MRI differ across the pathological subtypes of AD. MRI regional volumetric analysis can reliably track the distribution of neurofibrillary tangle pathology and can predict pathological subtype of AD at autopsy.

Funding

US National Institutes of Health (National Institute on Aging).

Introduction

Structural MRI measurements of brain atrophy are promising biomarkers for tracking disease progression in patients with Alzheimer's disease (AD). Progression of atrophy matches the stereotypical pattern of an increase in neurofibrillary tangles described by the Braak staging scheme,1, 2 with early changes in the medial temporal lobe (particularly the hippocampus) later spreading to the association cortex. The density of neurofibrillary tangles in the hippocampus correlates with the degree of atrophy on MRI,3, 4, 5 showing that atrophy is an ante-mortem correlate of neurofibrillary tangle pathology in elderly people.

However, 25% of patients with AD do not have the typical distribution of neurofibrillary tangles.⁶ In hippocampal-sparing disease, neurofibrillary tangle counts are increased in the cortex but low in the hippocampus, whereas in limbic-predominant cases, neurofibrillary tangle counts are unusually high in the hippocampus but reduced in the cortex.⁶ Clinical presentation, age at onset, disease duration, and rate of cognitive decline differ between these two subtypes and compared with patients who have typical distributions of neurofibrillary tangles (typical AD); therefore, they represent different clinicopathological subtypes of AD. Atypical subtypes could be an important confounder in MRI biomarker studies of AD. Whether patterns of atrophy on ante-mortem MRI differ across these subtypes is unknown.

The aim of our study was to establish whether ante-mortem patterns of volume loss on MRI differ between hippocampal-sparing, limbic-predominant, and typical AD, particularly in limbic and association cortices. We also investigated whether the ratio of hippocampal to cortical volumes on ante-mortem MRI could accurately predict these pathological subtypes at autopsy.

Section snippets

Study design and participants

Participants were identified from the neuropathological database of the Mayo Clinic (Rochester, MN, USA). To be eligible, participants had to fulfil several inclusion criteria: Braak stage IV or greater,¹ intermediate to high probability of AD according to the criteria of the National Institute on Aging and the Reagan Institute (NIA–Reagan),⁷ and have had an ante-mortem volumetric MRI.

All participants were recruited and followed up by the Mayo Clinic Alzheimer's Disease Research Center (ADRC;

Results

198 patients fulfilled inclusion criteria for the study, but 21 with hippocampal sclerosis were excluded from the study to avoid bias by low neurofibrillary tangle counts due to neuronal loss.⁶ Of the remaining 177 patients, 125 (71%) were classified as having typical AD, 33 (19%) as having limbic-predominant AD, and 19 (11%) as having hippocampal-sparing AD.

The three pathologically-defined AD groups did not differ in sex, education, APOE genotype, or disease duration (table 2). However, the

Discussion

Our study shows that patterns of atrophy on MRI vary between the three pathological subtypes of AD, supporting the pathological classification and suggesting that patterns of atrophy can predict during life the pathological subtype at autopsy. The ratio of hippocampal to cortical volumes provided the best discrimination between AD subtypes, with hippocampal-sparing AD showing the least hippocampal atrophy yet the most cortical atrophy, and vice versa for limbic-predominant disease. These

References (30)

ME Murray et al.
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study
Lancet Neurol
(2011)
J Ashburner et al.
Voxel-based morphometry—the methods
Neuroimage
(2000)
P Vemuri et al.
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies
Neuroimage
(2008)
J Ashburner et al.
Unified segmentation
Neuroimage
(2005)
N Tzourio-Mazoyer et al.
Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
Neuroimage
(2002)
JL Whitwell et al.
Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis
Neurobiol Aging
(2011)
H Braak et al.
Neuropathological stageing of Alzheimer-related changes
Acta Neuropathol
(1991)
JL Whitwell et al.
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study
Neurology
(2008)
CR Jack et al.
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
Neurology
(2002)
KM Gosche et al.
Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study
Neurology
(2002)

JG Csernansky et al.

Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects

Alzheimer Dis Assoc Disord

(2004)

BT Hyman et al.

Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease

J Neuropathol Exp Neurol

(1997)

RC Petersen et al.

Mayo Clinic Alzheimer's Disease Patient Registry

Aging (Milano)

(1990)

Diagnostic and Statistical Manual of Mental Disorders (DSM IV)

(1994)

SS Mirra et al.

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease

Neurology

(1991)

Cited by (333)

Revealing the heterogeneity of plasma protein and cognitive decline trajectory among Mild Cognitive Impairment patients by clustering of brain atrophy features
2024, Brain Multiphysics
Alzheimer's disease (AD) is suggested to be a heterogeneous disorder, but limited studies explore the heterogeneity of the Mild Cognitive Impairment (MCI) stage. This study aimed to tackle such problems using the CIMLR (Cancer Integration via Multikernel Learning) algorithm to cluster brain structural features extracted from T1-weighted Magnetic Resonance Images of MCI patients from Alzheimer's Disease Neuroimaging Initiative. The demographic and cognitive results, characteristics of brain structural features, plasma biomarkers, and longitudinal cognitive trajectory were analyzed for each cluster. The CIMLR clustering analysis revealed four distinct clusters. Cluster 1 is the oldest group but has had mild atrophy and moderate progression with elevated Tumor Necrosis Factor Receptor 2 level; and low Brain-Derived Neurotrophic Factor and CD40 Ligand levels. Cluster 2 showed the highest risk for aggressive MCI progression, with abnormal Leptin, Adiponectin, and Creatine kinase-MB values. Cluster 3 exhibited a low level of Monokine Induced by Gamma Interferon and mild atrophy that shared similar patterns with Cluster 1. Cluster 4 represented the healthiest group during longitudinal tracking, with the mildest Parahippocampal atrophy, which was found to be positively correlated with cognitive impairment and amino acid levels. The longitudinal analyses showed the potential of Hepatocyte Growth Factor as a marker for slow cognitive impairment; Cortisol and Neurofilament Light Polypeptide as prognosis markers for aggressive MCI progression. These findings may lay out new suggestions for further research contributing to the accurate diagnosis and precision medicine for dementia and AD.
Robustly uncovering the heterogeneity of neurodegenerative disease by using data-driven subtyping in neuroimaging: A review
2024, Brain Research
Neurodegenerative diseases are associated with heterogeneity in genetics, pathology, and clinical manifestation. Understanding this heterogeneity is particularly relevant for clinical prognosis and stratifying patients for disease modifying treatments. Recently, data-driven methods based on neuroimaging have been applied to investigate the subtyping of neurodegenerative disease, helping to disentangle this heterogeneity. We reviewed brain-based subtyping studies in aging and representative neurodegenerative diseases, including Alzheimer’s disease, mild cognitive impairment, frontotemporal dementia, and Lewy body dementia, from January 2000 to November 2022. We summarized clustering methods, validation, robustness, reproducibility, and clinical relevance of 71 eligible studies in the present study. We found vast variations in approaches between studies, including ten neuroimaging modalities, 24 cluster algorithms, and 41 methods of cluster number determination. The clinical relevance of subtyping studies was evaluated by summarizing the analysis method of clinical measurements, showing a relatively low clinical utility in the current studies. Finally, we conclude that future studies of heterogeneity in neurodegenerative disease should focus on validation, comparison between subtyping approaches, and prioritise clinical utility.
Tau trajectory in Alzheimer's disease: Evidence from the connectome-based computational models
2023, Brain Research Bulletin
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with an impairment of cognition and memory. Current research on connectomics have now related changes in the network organization in AD to the patterns of accumulation and spread of amyloid and tau, providing insights into the neurobiological mechanisms of the disease. In addition, network analysis and modeling focus on particular use of graphs to provide intuition into key organizational principles of brain structure, that stipulate how neural activity propagates along structural connections. The utility of connectome-based computational models aids in early predicting, tracking the progression of biomarker-directed AD neuropathology. In this article, we present a short review of tau trajectory, the connectome changes in tau pathology, and the dependent recent connectome-based computational modelling approaches for tau spreading, reproducing pragmatic findings, and developing significant novel tau targeted therapies.
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
2023, Revue Neurologique
Alzheimer's disease (AD) is a multi-etiology disease. The biological system of AD is associated with multidomain genetic, molecular, cellular, and network brain dysfunctions, interacting with central and peripheral immunity. These dysfunctions have been primarily conceptualized according to the assumption that amyloid deposition in the brain, whether from a stochastic or a genetic accident, is the upstream pathological change. However, the arborescence of AD pathological changes suggests that a single amyloid pathway might be too restrictive or inconsistent with a cascading effect. In this review, we discuss the recent human studies of late-onset AD pathophysiology in an attempt to establish a general updated view focusing on the early stages. Several factors highlight heterogenous multi-cellular pathological changes in AD, which seem to work in a self-amplifying manner with amyloid and tau pathologies. Neuroinflammation has an increasing importance as a major pathological driver, and perhaps as a convergent biological basis of aging, genetic, lifestyle and environmental risk factors.
Conv-Swinformer: Integration of CNN and shift window attention for Alzheimer's disease classification
2023, Computers in Biology and Medicine
Deep learning (DL) algorithms based on brain MRI images have achieved great success in the prediction of Alzheimer’s disease (AD), with classification accuracy exceeding even that of the most experienced clinical experts. As a novel feature fusion method, Transformer has achieved excellent performance in many computer vision tasks, which also greatly promotes the application of Transformer in medical images. However, when Transformer is used for 3D MRI image feature fusion, existing DL models treat the input local features equally, which is inconsistent with the fact that adjacent voxels have stronger semantic connections than spatially distant voxels. In addition, due to the relatively small size of the dataset for medical images, it is difficult to capture local lesion features in limited iterative training by treating all input features equally. This paper proposes a deep learning model Conv-Swinformer that focuses on extracting and integrating local fine-grained features. Conv-Swinformer consists of a CNN module and a Transformer encoder module. The CNN module summarizes the planar features of the MRI slices, and the Transformer module establishes semantic connections in 3D space for these planar features. By introducing the shift window attention mechanism in the Transformer encoder, the attention is focused on a small spatial area of the MRI image, which effectively reduces unnecessary background semantic information and enables the model to capture local features more accurately. In addition, the layer-by-layer enlarged attention window can further integrate local fine-grained features, thus enhancing the model’s attention ability. Compared with DL algorithms that indiscriminately fuse local features of MRI images, Conv-Swinformer can fine-grained extract local lesion features, thus achieving better classification results.
Frontal variant Alzheimer's disease: A systematic narrative synthesis
2023, Cortex
Frontal variant Alzheimer's disease (fvAD) is considered a rare form of Alzheimer's disease (AD) which may be misdiagnosed as behavioural variant frontotemporal dementia (bvFTD). The literature has tended to conflate behavioural and executive dysfunction in fvAD cohorts and uses both AD diagnostic criteria and bvFTD diagnostic criteria to classify fvAD cohorts. The primary aim of this narrative synthesis was to summarise neuropsychological findings in fvAD cohorts in the context of established AD pathology.
EMBASE, PsycINFO, PROQUEST and MEDLINE databases were searched for studies eligible for inclusion. Studies with both neuropsychological and biomarker evidence were included in the final narrative synthesis.
Ten studies were reviewed, including samples totalling 342 fvAD participants, 178 typical AD participants and 250 bvFTD participants. The review revealed areas worthy of further investigation that may aid differential diagnosis, including the degree of executive dysfunction in fvAD cohorts relative to bvFTD cohorts, the onset of behavioural and cognitive symptomatology, and similarities between fvAD and typical AD cognitive profiles.
There was insufficient neuropsychological evidence to clearly differentiate fvAD and bvFTD cognitive phenotypes, however, the review has highlighted distinctive features of the two disorders that may guide differential diagnosis in future research. Moreover, the review has highlighted issues involving disparate diagnostic criteria used to classify fvAD cohorts, contributing to variation in findings.

View all citing articles on Scopus

View full text

ArticlesNeuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study

Summary

Background

Methods

Findings

Interpretation

Funding

Introduction

Section snippets

Study design and participants

Results

Discussion

Lancet Neurol

Neuroimage

Neuroimage

Neuroimage

Neuroimage

Neurobiol Aging

Neuropathological stageing of Alzheimer-related changes

Acta Neuropathol

MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study

Neurology

Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

Neurology

Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study

Neurology

Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects

Alzheimer Dis Assoc Disord

Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease

J Neuropathol Exp Neurol

Mayo Clinic Alzheimer's Disease Patient Registry

Aging (Milano)

Diagnostic and Statistical Manual of Mental Disorders (DSM IV)

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease

Neurology

Articles
Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study